Swedish dermatology specialist Lipidor and Cadila Pharmaceuticals, one of India’s largest privately-held pharma companies, have announced that they will collaborate on a Phase III trial and the joint commercialization of a psoriasis product.
The product concerned is a sprayable anti-psoriatic agent consisting of the generic vitamin D analogue, calcipotriol, formulated with Lipidor´s patented lipid-based drug delivery technology, Akvano.
The treatment is being developed for patients with mild to moderate psoriasis. Under the agreement, Cadila Pharmaceuticals will conduct a Phase III program in India, starting later this year.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze